{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:56:25Z","timestamp":1791860185073,"version":"4.3.4"},"reference-count":40,"publisher":"Impact Journals, LLC","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,4,19]]},"DOI":"10.18632\/oncotarget.8010","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T08:22:52Z","timestamp":1457598172000},"page":"21982-21990","source":"Crossref","is-referenced-by-count":57,"title":["Next-generation sequencing for sensitive detection of <i>BCR-ABL1<\/i> mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients"],"prefix":"10.18632","volume":"7","author":[{"given":"Simona","family":"Soverini","sequence":"first","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"De Benedittis","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina Machova","family":"Polakova","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Blood Transfusion, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Linhartova","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Blood Transfusion, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Gugliotta","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Mancini","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Klamova","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Blood Transfusion, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Salvucci","sequence":"additional","affiliation":[{"name":"Oncology-Hematology Department, \u201cS. Maria delle Croci\u201d Hospital, Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Crugnola","sequence":"additional","affiliation":[{"name":"Hematology, Parma University Hospital, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[{"name":"Division of Haematology, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Albano","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[{"name":"Unit of Blood Disease and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,3,9]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications ofkinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Shah","year":"2014","journal-title":"Leuk Res"},{"key":"2","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2217\/pgs.12.103","article-title":"Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis","volume":"13","author":"Baccarani","year":"2012","journal-title":"Pharmacogenomics"},{"key":"3","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Jones","year":"2007","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Shou","year":"2009","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Hochhaus","year":"2009","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1200\/JCO.2006.08.9128","article-title":"Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia","volume":"24","author":"Marzocchi","year":"2006","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Gugliotta","year":"2009","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Cross","year":"2011","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Haluska","year":"2012","journal-title":"N Engl J Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Kantarjian","year":"2013","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1053\/j.seminhematol.2009.01.009","article-title":"Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia","volume":"46","author":"Soverini","year":"2009","journal-title":"Semin Hematol"},{"key":"12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/leu.2009.193","article-title":"Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history","volume":"24","author":"Kantarjian","year":"2010","journal-title":"Leukemia"},{"key":"13","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.25717","article-title":"Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Cancer"},{"key":"14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MOH.0b013e32834399ef","article-title":"Mutational analysis in chronic myeloid leukemia: when and what to do?","volume":"18","author":"Hughes","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ajh.22272","article-title":"kinase domain mutations: methodology and clinical evaluation","volume":"87","author":"Apperley","year":"2012","journal-title":"Am J Hematol"},{"key":"16","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","article-title":"Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain","volume":"122","author":"Bochicchio","year":"2013","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Horowitz","year":"2006","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"19","first-page":"659","article-title":"Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib","volume":"91","author":"Kim","year":"2006","journal-title":"Haematologica"},{"key":"20","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/sj.leu.2403983","article-title":"Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL","volume":"19","author":"Skogen","year":"2005","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.leu.2404554","article-title":"Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib","volume":"21","author":"Deininger","year":"2007","journal-title":"Leukemia"},{"key":"23","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1038\/leu.2008.180","article-title":"Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR","volume":"22","author":"Lange","year":"2008","journal-title":"Leukemia"},{"key":"24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1373\/clinchem.2009.133843","article-title":"Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment","volume":"56","author":"Mikkola","year":"2010","journal-title":"Clin Chem"},{"key":"25","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3324\/haematol.2009.006981","article-title":"A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib","volume":"94","author":"Lange","year":"2009","journal-title":"Haematologica"},{"key":"26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/leu.2011.187","article-title":"Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients","volume":"26","author":"Hochhaus","year":"2012","journal-title":"Leukemia"},{"key":"27","article-title":"SNP genotyping using the Sequenom MassARRAY iPLEX platform","author":"Tabbaa","year":"2009","journal-title":"Curr Protoc Hum Genet"},{"key":"28","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1200\/JCO.2011.35.0934","article-title":"Sensitive detection ofmutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy","volume":"29","author":"Branford","year":"2011","journal-title":"J Clin Oncol"},{"key":"29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Hochhaus","year":"2008","journal-title":"Haematologica"},{"key":"30","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/leu.2011.155","article-title":"The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories","volume":"25","author":"Iacobucci","year":"2011","journal-title":"Leukemia"},{"key":"31","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.12194","article-title":"Next-generation sequencing - feasibility and practicality in haematology","volume":"160","author":"Haferlach","year":"2013","journal-title":"Br J Haematol"},{"key":"32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jmoldx.2013.03.003","article-title":"Robustness of amplicon deep sequencing underlines its utility in clinical applications","volume":"15","author":"Kohlmann","year":"2013","journal-title":"J Mol Diagn"},{"key":"33","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood.V122.21.743.743","article-title":"The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories","volume":"122","author":"Hernandez","year":"2013","journal-title":"Blood"},{"key":"34","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/humu.22332","article-title":"Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics","volume":"34","author":"Sinke","year":"2013","journal-title":"Hum Mutat"},{"key":"35","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Guarini","year":"2014","journal-title":"Blood"},{"key":"36","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2014.297","article-title":"Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia","volume":"29","author":"Plevova","year":"2015","journal-title":"Leukemia"},{"key":"37","doi-asserted-by":"crossref","first-page":"e81975","DOI":"10.1371\/journal.pone.0081975","article-title":"Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma","volume":"8","author":"Choi","year":"2013","journal-title":"PLoS One"},{"key":"38","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1373\/clinchem.2004.031112","article-title":"Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib","volume":"50","author":"Baccarani","year":"2004","journal-title":"Clin Chem"},{"key":"39","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Tiribelli","year":"2006","journal-title":"Clin Cancer Res"},{"key":"40","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","article-title":"Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase","volume":"141","author":"Hochhaus","year":"2015","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.8010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T19:25:53Z","timestamp":1589225153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.8010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,9]]},"references-count":40,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2016,4,19]]}},"alternative-id":["8010","26980736"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.8010","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,9]]}}}